Sorivudine

Summary

Sorivudine (CHEMBL70046) is an approved small molecule; indicated across 2 conditions including herpes zoster.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 349.13 Da · C11H13BrN2O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL70046
Name	Sorivudine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282192
Molecular formula	C11H13BrN2O6
Molecular weight	349.13
InChIKey	GCQYYIHYQMVWLT-HQNLTJAPSA-N

SMILES: C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)/C=C/Br

IUPAC name: 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione

Also known as: Bravavir, Brovavir, Bv-arau, SO 32,756, SO-32756, Sorivudina, Sorivudine, SQ 32,756, SQ-32756, YN-72, SORIVUDINE, BROVAVIR

Patent coverage: 965 distinct patent families (3,507 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Thymidine kinase, Thymidine kinase 2, mitochondrial, Deoxynucleoside kinase, Thymidine kinase.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P09250	5.5	IC50	3200	nM	CHEMBL_ACT_2024231
Q9QNF7	5.44	IC50	3600	nM	CHEMBL_ACT_2024187

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
herpes zoster	2	MONDO:0005609	EFO:0006510

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002358	PHASE3	COMPLETED	A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
NCT00000953	PHASE2	COMPLETED	Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).